Cost-effectiveness and budget impact analysis of viscosupplementation with hylan G-F 20 for knee and hip osteoarthritis

References

• Migliore A, Procopio S. Effectiveness and utility of hyaluronic acid in osteoarthritis. Mini Rev Clin Cases Mineral Bone Metab. 2015;12(1):31–33.
   PubMedGoogle Scholar
• Symmons D, Mathers C, Pfleger B. Global Burden of Osteoarthritis in the Year 2000. Geneva: World Health Organization; 2003 Available from: http://www.who.int/healthinfo/statistics/bod_osteoarthritis.pdf.
   Google Scholar
• Mathers CD, Vos ET, Stevenson CE, Begg SJ. The Australian burden of disease study: measuring the loss of health from diseases, injuries and risk factors. Med J Aust. 2000;172:592–596.10914105
   PubMed Web of Science ®Google Scholar
• D’Ambrosia RD. Epidemiology of osteoarthritis. Orthopedics. 2005;28 Suppl:S201–5.15747607
   PubMed Web of Science ®Google Scholar
• Hunter DJ, Neogi T, Hochberg MC. Quality of osteoarthritis management and the need for reform in the US. Arthritis Care Res (Hoboken). 2011;63(1):31–38. doi:10.1002/acr.2027820583113
   PubMed Web of Science ®Google Scholar
• Murphy L, Schwartz TA, Helmick CG, et al. Lifetime risk of symptomatic knee osteoarthritis. Arthritis Rheum. 2008;59(9):1207–1213. doi:10.1002/art.2402118759314
   PubMed Web of Science ®Google Scholar
• Murphy LB, Helmick CG, Schwartz TA, et al. One in four people may develop symptomatic hip osteoarthritis in his or her lifetime. Osteoarthritis Cartilage. 2010;18(11):1372–1379. doi:10.1016/j.joca.2010.08.00520713163
   PubMed Web of Science ®Google Scholar
• Ricci JA, Stewart WF, Chee E, Leotta C, Foley K, Hochberg MC. Pain exacerbation as a major source of lost productive time in US workers with arthritis. Arthritis Rheum. 2005;53:673–681. doi:10.1002/art.2145316208644
   PubMed Web of Science ®Google Scholar
• Woolf AD. The bone and joint decade 2000–2010. Ann Rheum Dis. 2000;59:81–82. doi:10.1136/ard.59.2.8110666159
   PubMed Web of Science ®Google Scholar
• Piscitelli P, Iolascon G, Di Tanna G, et al. Socioeconomic burden of total joints arthroplasty for symptomatic hip and knee osteoarthritis inthe Italian population: a 5-year analysis based on hospitalization records. Arthritis Care Res. 2012;64:1320–1327. doi:10.1002/acr.21706
   Google Scholar
• Migliore A, Tormenta S, Martin LS, et al. The symptomatic effects of intra-articular administration of hylan GF 20 on osteoarthritis of the hip: clinical data of 6 months follow-up. Clin Rheumatol. 2006;25:389–393. doi:10.1007/s10067-005-0052-x16249827
   PubMed Web of Science ®Google Scholar
• John R, Watterson JR, Esdaile JM. Viscosupplementation: therapeutic mechanisms andclinical potential in osteoarthritis of the knee. J Am Acad Orthop Surg. 2000;8:277–284.11029555
   PubMedGoogle Scholar
• American College of Rheumatology Subcommittee on osteoarthritis guidelines recommendations for the medical management of osteoarthritis of the hip and the knee: 2000 update. Arthritis Rheum. 2000;43:1905–1915. doi:10.1002/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P11014340
   PubMed Web of Science ®Google Scholar
• Pendleton A, Arden N, Dougados M, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2000;59:936–944. doi:10.1136/ard.59.12.93611087696
   PubMed Web of Science ®Google Scholar
• Chevalier X, Jerosch J, Goupille P, et al. Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial. Ann Rheum Dis. 2010;69:113–119. originally published online March 19, 2009. doi:10.1136/ard.2008.09462319304567
   PubMed Web of Science ®Google Scholar
• Sarvajeet Pal, Sreedhar Thuppal, Reddy KJ, et al. Long-term (1-year) safety and efficacy of a single 6-mL injection of Hylan G-F 20 in Indian patients with symptomatic knee osteoarthritis. Open Rheumatol J. 2014;8:54–68. doi:10.2174/187431290140801005425328555
   PubMedGoogle Scholar
• Migliore A, Giovannangeli F, Granata M, et al. Hylan G-F 20: review of its safety and efficacy in the management of joint pain in osteoarthritis, clinical medicine insights: arthritis and musculoskeletal disorders. 2010;3:55–68.
   Google Scholar
• Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2006;14(2):154–162. doi:10.1016/j.joca.2005.09.00316242361
   PubMedGoogle Scholar
• Briggs KK, Matheny LM, Steadman JR. Can hylan g-f 20 with corticosteroid meet the expectations of osteoarthritis patients? Am J Orthop (Belle Mead NJ). 2012;41(7):311–315.22893881
   PubMedGoogle Scholar
• Berkowitz DF. Proceedings of the United States. Food and Drug Administration Advisory Panel on Orthopedic and Rehabilitation Devices VA: CASET Associates; 1996.
   Google Scholar
• Pavelka K, Gatterova J, Altman RD. Radiographic progression of knee osteoarthritis in a Czech cohort. Clin Exp Rheumatol. 2000;18:473–477.10949722
   PubMed Web of Science ®Google Scholar
• Jordan JM, Sowers MF, Messier SP, et al. Methodologic issues in clinical trials for prevention or risk reduction in osteoarthritis. Osteoarthritis Cartilage. 2011;19:500–508. doi:10.1016/j.joca.2010.10.03121396470
   PubMed Web of Science ®Google Scholar
• Weinstein AM, Benjamin N. Rome estimating the burden of total knee replacement in the United States. J Bone Joint Surg Am. 2013;95(5):385–392. doi:10.2106/JBJS.L.0020623344005
   PubMedGoogle Scholar
• Chawla H, van der List JP, Christ AB, et al. Annual revision rates of partial versus total knee arthroplasty: a comparative meta-analysis. Knee. 2017;24(2):179–190. doi:10.1016/j.knee.2016.11.00627916580
   PubMed Web of Science ®Google Scholar
• Katz JN, Smith SR, Collins JE, et al. Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities. Osteoarthritis Cartilage. 2016;24(3):409–418. doi:10.1016/j.joca.2015.10.00626525846
   PubMedGoogle Scholar
• Memtsoudis SG, Besculides MC, Gaber L, Liu S, González Della VA. Risk factors for pulmonary embolism after hip and knee arthroplasty: a population-based study. Int Orthop. 2009;33(6):1739–1745. doi:10.1007/s00264-008-0659-z18925395
   PubMedGoogle Scholar
• Nuesch E, Dieppe P, Reichenbach S, Williams S, Iff S, Juni P. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ. 2011;342:d1165. doi:10.1136/bmj.d116521385807
   PubMed Web of Science ®Google Scholar
• Cannon GW, Cladwell JR, Holt P, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis Rheum. 2000;43(5):978–987. doi:10.1002/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-010817549
   PubMed Web of Science ®Google Scholar
• James WH, Ward JR, Egger MJ, et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum. 1993;36(9):1196–1206. doi:10.1002/art.17803609048216413
   PubMedGoogle Scholar
• Kamath CC, Kremers HM, Vanness DJ, O’Fallon WM, Cabanela RL, Gabriel SE. The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. Value Health. 2003;6(2):144–157. doi:10.1046/j.1524-4733.2003.00215.x12641865
   PubMed Web of Science ®Google Scholar
• Conrozier T, Jerosch J, Beks P, et al. Prospective, multi-centre, randomised evaluation of the safety and efficacy of five dosing regimens of viscosupplementation with hylan G-F 20 in patients with symptomatic tibio-femoral osteoarthritis: a pilot study. Arch Orthop Trauma Surg. 2009;129(3):417–423. doi:10.1007/s00402-008-0601-218365224
   PubMedGoogle Scholar
• Gerzeli S, Tarricone R, Zolo P, Colangelo I, Busca MR, Gandolfo C. The economic burden of stroke in Italy. The EcLIPSE study: economic longitudinal incidence-based project for stroke evaluation. Neurol Sci. 2005;26(2):72–80. doi:10.1007/s10072-005-0439-015995823
   PubMedGoogle Scholar
• Sturkenboom MCJM, Romano F, Simon G, et al. The iatrogenic costs of NSAID therapy: a population study. Arthritis Care Res (Hoboken). 2002;47(2):132–140. doi:10.1002/art.10268
   Web of Science ®Google Scholar
• Migliore A Prof. Heads of Rheumatology Unit at San Pietro Hospital in Rome and President of ANTIAGE Registry (2017, September-October). Personal interview.
   Google Scholar
• Nomenclatore prestazioni ambulatoriali 2013. Italian Ministry of Health. Available from: http://www.salute.gov.it/portale/temi/p2_6.jsp?id=3662&area=programmazioneSanitariaLea&menu=vuoto.
   Google Scholar
• Migliore A, Martini LSM, Alimonti A, Valente C, Tormenta S. Efficacy and safety of viscosupplementation by ultrasound-guided intra-articular injection in osteoarthritis of the hip. Osteo Arthritis Cartilage. 2003;11:305–306. doi:10.1016/S1063-4584(03)00008-6
   PubMed Web of Science ®Google Scholar
• Kingsbury SR, Gross HJ, Isherwood G, Conaghan PG. Osteoarthritis in Europe: impact on health status, work productivity and use of pharmacotherapies in five European countries. Rheumatology (Oxford). 2014;53(5):937–947. doi:10.1093/rheumatology/ket46324489012
   PubMed Web of Science ®Google Scholar
• OECD. (2016). Average annual wages. Available from: https://stats.oecd.org/Index.aspx?DataSetCode=AV_AN_WAGE.
   Google Scholar
• Drummond M, Sculpher M, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Fourth ed. Oxford, UK: Oxford University Press; 2015.
   Google Scholar
• Thomas T, Amouroux F, Vincent P. Intra articular hyaluronic acid in the management of knee osteoarthritis: pharmaco-economic study from the perspective of the national health insurance system. PLoS One. 2017;12(3):e0173683. doi:10.1371/journal.pone.017368328328935
   PubMedGoogle Scholar
• Waddell DD, Bricker DC. Total knee replacement delayed with Hylan G-F 20 use in patients with grade IV osteoarthritis. J Manag Care Pharm. 2007;13(2):113–121.17330972
   PubMed Web of Science ®Google Scholar
• Van Den Bekerom MPJ, Rys B, Mulier M. Viscosupplementation in the hip: evaluation of hyaluronic acid formulations. Arch Orthop Trauma Surg. 2008;128(3):275–280. doi:10.1007/s00402-007-0374-z17572901
   PubMed Web of Science ®Google Scholar
• Mencacci C, Di Sciascio G, Katz P, Ripellino C. Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy. Clinicoecon Outcomes Res. 2013;5:87–99. doi:10.2147/ceor.s3949223413176
   PubMedGoogle Scholar
• Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006;(1):CD004257. doi:10.1002/14651858.CD004257.pub216437479
   PubMed Web of Science ®Google Scholar
• Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006;(2):CD005321. doi:10.1002/14651858.CD005321.pub216625635
   PubMedGoogle Scholar